W
William H. Sharfman
Researcher at Johns Hopkins University
Publications - 81
Citations - 22837
William H. Sharfman is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 33, co-authored 74 publications receiving 19237 citations. Previous affiliations of William H. Sharfman include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Journal ArticleDOI
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Journal ArticleDOI
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz,Jonathan J. Havel,Vladimir Makarov,Alexis Desrichard,Walter J. Urba,Jennifer S. Sims,F. Stephen Hodi,Salvador Martín-Algarra,Rajarsi Mandal,William H. Sharfman,Shailender Bhatia,Wen-Jen Hwu,Thomas F. Gajewski,Craig L. Slingluff,Diego Chowell,Sviatoslav M. Kendall,Han Chang,Rachna Shah,Fengshen Kuo,Luc G. T. Morris,John-William Sidhom,Jonathan P. Schneck,Christine Horak,Nils Weinhold,Timothy A. Chan +24 more
TL;DR: Comprehensive genomic profiling data in this study provide insight into nivolumab's mechanism of action and reveal expansion of T cell clones in the setting of neoantigen loss.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.